Knight Therapeutics Overview
Get informed when a big investor buys or sells
+ Follow76.61
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for KHTRF is 76.61. That is above the sector sector average of 24.62. Investors often review this figure alongside Knight Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, KHTRF currently prints 76.61 for P/E ratio, while the sector average sits near 24.62. That is roughly 211.1% above the sector mean. Large gaps often invite a closer look at Knight Therapeutics's growth, margins, and balance sheet.
A P/E ratio of 76.61 for Knight Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (24.62) and with KHTRF's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting KHTRF's P/E ratio (76.61), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
